Comprehensive infection control measures prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection: A single-center prospective cohort study and seroprevalence survey종합감염관리대책으로 병원획득 중증급성호흡기증후군 코로나바이러스 2 감염 예방: 단일기관 전향 코호트 연구 및 혈청유병률 조사Research Article Published on 2021-10-112022-09-12 Journal: PLoS ONE [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adhere age All participant All participants anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody baseline Care city cohort study Comprehensive confidence coronavirus coronavirus disease COVID-19 COVID-19 patient cross-sectional disease Effectiveness Elecsy Elecsys engage HCW HCWs healthcare worker Healthcare workers high mortality rate hospital in-patient infection control Infection prevention Infectious disease Japan measure Measures Medical care Nurse Nurses Older Other participant participated Personal protective equipment positive precautions Prevent Primary outcome prospective cohort prospective cohort study provided remained Result risk risk factor SARS-CoV-2 SARS-COV-2 infection seroprevalence survey severe acute respiratory syndrome Coronavirus Sex single-center study period tested Transmission treated [DOI] 10.1371/journal.pone.0257513 PMC 바로가기 [Article Type] Research Article
Humoral Response to SARS-CoV-2 Vaccine of a Patient Receiving Methotrexate Treatment and Implications for the Need of MonitoringCase Report Published on 2021-10-092022-10-28 Journal: Vaccines [Category] COVID-19, [키워드] AIIRD antibody antibody level assays Autoimmune disease Autoimmune diseases COVID-19 COVID-19 mortality diagnosed DiaSorin dose drug Elecsy female IgG immunomodulatory medications Immunomodulatory therapies indicate inhibitor LIAISON methotrexate monitoring MTX Necrosis Other Patient positive result receiving Research response rheumatoid arthritis risk Roche Diagnostics SARS-CoV-2 serum tested the antibody response TNFis treated Treatment vaccination Vaccinations Vaccine were measured [DOI] 10.3390/vaccines9101151 PMC 바로가기 [Article Type] Case Report
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD인플릭시맙은 IBD 환자에서 BNT162b2 및 ChAdOx1 nCoV-19 SARS-CoV-2 백신에 대한 면역원성 약화와 관련이 있습니다.Article Published on 2021-10-012022-09-12 Journal: Gut [Category] MERS, SARS, 진단, [키워드] 95% CI age anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibody antibody concentration Antibody concentrations Antibody Response Autoimmune Autoimmune disease BNT162b2 BNT162b2 vaccine bowel ChAdOx1 ChAdOx1 nCoV-19 CLARITY Cohort Concentration concentrations COVID-19 cut-off defined Delayed disease dose Effectiveness Elecsy Evidence Fold change geometric mean IBD Immunity immunomodulator Infection Inflammatory Inflammatory bowel disease Inflammatory diseases infliximab investigated monoclonal antibody Multivariable models of BNT162b2 outcome Patient patients patients treated Primary outcome SARS-COV-2 infection SARS-CoV-2 vaccination SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose secondary Seroconversion seroconversion rate serological response single dose smoking TNF treated vaccination Vaccine Vaccines vedolizumab [DOI] 10.1136/gutjnl-2021-324789 PMC 바로가기 [Article Type] Article
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity리툭시맙 치료 환자에서 SARS-CoV-2 백신 접종: T 세포 매개 면역이 있는 경우 B 세포가 체액성 면역 반응을 촉진합니다Article Published on 2021-10-012022-09-11 Journal: Annals of the rheumatic diseases [Category] MERS, SARS, 진단, 치료기술, [키워드] Affect antibody assays B cell B cells BNT162b2 CD19 controls correlated COVID-19 detectable develop Elecsy enzyme enzyme-linked immunosorbent except for healthy control healthy individual healthy individuals humoral humoral immune response humoral immune responses IFN-γ immune response immune responses immunisation immunoassay independent independent of induce levels of antibody mounted mRNA mRNA-1273 n=36 neutralisation neutralisation tests Neutralising Antibodies neutralising antibody one patient Patient patients peripheral B cell peripheral B cells promote protective effect Protective effects quantified RBD Receptor-binding domain responses rituximab RTX SARS-CoV-2 SARS-CoV-2 RBD SARS-CoV-2 vaccination SARS-CoV-2-specific antibodies SARS-CoV-2-specific antibody SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells SARS-CoV-2-specific T-cell response SARS-CoV-2-specific T-cell responses seroconverted significantly specific antibodies Spike protein T cells T-cell responses T-cell-mediated immunity the patient the receptor-binding domain the SARS-CoV-2 the spike protein therapy Treatment vaccination [DOI] 10.1136/annrheumdis-2021-220781 PMC 바로가기 [Article Type] Article
High-throughput immunoassays for SARS-CoV-2 – considerable differences in performance when comparing three methodsSARS-CoV-2에 대한 고처리량 면역분석 - 세 가지 방법을 비교할 때 성능의 상당한 차이Article Published on 2021-10-012022-09-11 Journal: Infectious diseases (London, England) [Category] MERS, SARS, 진단, 치료기술, [키워드] (Abbott 2019 Abbott analysed antibodies antibody assays Biotechnology caution China Clinical use contributed COVID-19 COVID-19 pandemic criteria cross-reactive DiaSorin Elecsy Elecsys evaluated exhibiting highest IgG immunoassay immunology Italy Lateral flow test LIAISON park performed positive individual Rapid Rapid test Regulatory Authorities regulatory authority Roche RT-PCR S1/S2 SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2 RT-PCR sensitivity serology specificity Test Tianjin [DOI] 10.1080/23744235.2021.1931434 PMC 바로가기 [Article Type] Article
The strength of association between pre-and post-booster BNT162b2 anti-SARS-CoV-2 antibodies levels depends on the immunoassay사전 및 사후 부스터 BNT162b2 항 SARS-CoV-2 항체 수준 간의 연관성 강도는 면역 분석에 따라 다릅니다.Observational Study Published on 2021-10-012022-09-12 Journal: International Journal of Infectious Diseases [Category] MERS, SARS, 임상, 진단, [키워드] age anti-SARS-CoV-2 anti-SARS-CoV-2 antibody antibodies association baseline BNT162b2 BNT162b2 vaccine booster clinical effectiveness commercial immunoassay coronavirus disease correlation COVID-19 determine dose Elecsy enrolled Evidence females healthcare worker highest homologous humoral IgG immunoassay immunoassays initial LIAISON Pearson predicted Roche S-RBD SARS-CoV-2 SARS-CoV-2 IgG second dose seronegative serum serum antibody significantly the immunoassay vaccination Vaccine vaccine dose were assessed [DOI] 10.1016/j.ijid.2021.08.059 PMC 바로가기 [Article Type] Observational Study
Serological Assays for Assessing Postvaccination SARS-CoV-2 Antibody Response백신 접종 후 SARS-CoV-2 항체 반응을 평가하기 위한 혈청학적 분석Research Article Published on 2021-09-292022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 진단, 치료기술, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody Assessing balance best characteristic CLIA confidence coronavirus Cost effectiveness country COVID-19 COVID-19 pandemic Cutoff cutoff value DiaSorin Elecsy Elecsys ELISA enzyme evaluated False negative false negatives gold gold standard highest highlight IgG immune response Immune status immunosorbent knowledge limitation mass neutralization neutralization test optimization pandemic parameter plaque reduction neutralization Population positive postvaccination Predictive predictive values PRNT receiver receiver operating characteristic required respiratory response ROC Roche S1/S2 SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 IgG sensitivity Serological assay serological assays severe acute respiratory syndrome Coronavirus significantly increased specificity surrogate virus neutralization test Surveillance understanding vaccinate vaccination virus neutralization test [DOI] 10.1128/Spectrum.00733-21 PMC 바로가기 [Article Type] Research Article
SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: adult population-based cross-sectional studyVirology Published on 2021-09-202022-10-28 Journal: PeerJ [Category] COVID-19, [키워드] 95% CI Adults altitude anti-SARS-CoV-2 anti-SARS-CoV-2 antibody chemiluminescence conducted COVID cross-sectional Cusco diagnosis of SARS-CoV-2 died ecological effort Elecsy enrolled Face shield facial Factor First wave FIVE IgM and IgG Infection Mask participant Peru positive positive COVID-19 Prevalence Probability proportion reduced Result SARS-CoV-2 SARS-CoV-2 seroprevalence seropositive Seroprevalence serum significant difference susceptible Symptom total antibody wearing [DOI] 10.7717/peerj.12149 PMC 바로가기 [Article Type] Virology
From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany)Research Article Published on 2021-09-082022-10-28 Journal: BMC Infectious Diseases [Category] COVID-19, SARS, [키워드] 95% CI activity addition adjusted age age and sex analysed baseline Blood capillary blood Clustering collected Contact Course COVID-19 COVID-19 cohort COVID-19 pandemic Elecsy explained Factor Follow-up General population Germany Health highest Infection information knowledge majority men Mild symptom Munich offered ORCHESTRA pandemic participant Participants Population-based cohort study positive potential risk public health measure remained Result risk risk factor Roche SARS-CoV-2 SARS-CoV-2 antibody sensitivity Sensitivity analyses Sero-incidence Sero-prevalence specificity supplementary material Surveillance Taking tested took place while [DOI] 10.1186/s12879-021-06589-4 PMC 바로가기 [Article Type] Research Article
SARS-CoV-2 serology: Validation of high-throughput chemiluminescent immunoassay (CLIA) platforms and a field study in British ColumbiaSARS-CoV-2 혈청학: 브리티시컬럼비아에서 고처리량 화학발광 면역분석(CLIA) 플랫폼 및 현장 연구 검증Article Published on 2021-09-012022-09-11 Journal: Journal of Clinical Virology [Category] SARS, 진단, 치료기술, [키워드] Abbott addition adjunct Antibody testing assays automated Care chemiluminescent immunoassay CLIA collected COVID-19 demonstrated diagnose diagnoses DiaSorin Disease prevalence Elecsy evaluated field Infection LIAISON molecular Negative predictive value Ortho Vitros outbreak Outbreak investigation outbreak investigations PCR PCR testing performed platform Positive predictive value positive predictive values post-symptom onset PPV predictive values Prevalence required Roche S1/S2 SARS-CoV-2 SARS-CoV-2 antibody SARS-CoV-2 antibody testing sensitivities sensitivity Sensitivity and specificity serologic serologic testing serology Siemen Siemens Specificities tested Total vaccine response validation validation study [DOI] 10.1016/j.jcv.2021.104914 PMC 바로가기 [Article Type] Article